|Etravirine (TMC-125) Clinical Trial?
Oct 17, 2008
I was diagnosed in September 2007 and due to my CD4 count going marginally below 350 on 3 consecutive occasions my doctor prescribed Atripla for me 3 months ago. My viral load before medication was around 100,000 copies and my last blood test after being on Atripla for a month had reduced that to 724, however the side effects are quite hard at times and I have mood swings and some feelings of low depression. I visited my doctor yesterday and she has recommended that I go on a clinical trial for 6 months with Etravirine (TMC-125. Everything seems to be moving rather fast and I'm unsure what to do next, do you think that Etravirine (TMC-125)will be a better alternative for me even though I will need to take 6 tablets a day instead of 1?
| Response from Dr. Henry
Etravirine can be effective after failing efavirenz based therapy depending on the resistance picture. Use of etravirine may be one reasonable option as would a switch to a boosted protease inhibitor based regimen depending on your entire treatment and resistance history. KH
Get Email Notifications When This Forum Updates or Subscribe With RSS
- Dry Cough After Oral Sex On A Woman What Are The Chances Of HIV
- Hpv After Swallowing Sperm Worried I Have HIV
- Swollen Lymph Glands After Erotic Massage Worried I Have HIV
- Swollen Lymph Glands After Sucking Penis Worried I Have HIV
- White Spots After Condom Inside Out Worried I Have HIV
- Chances Of Getting Cervical Cancer If You Are Monogamous
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.